|Day Low/High||14.45 / 14.95|
|52 Wk Low/High||7.02 / 17.80|
Dr. Copeland to Remain a Key Advisor to Epizyme Following Transition
Investors in Epizyme Inc. saw new options begin trading this week, for the April 21st expiration.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Epizyme Inc. saw new options begin trading this week, for the August 18th expiration.
Investors considering a purchase of Epizyme Inc. shares, but cautious about paying the going market price of $11.80/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Robert A. Copeland, Ph.D., recognized for his insights into epigenetic targets contributing to the development of novel investigational medicines
Studies Will Evaluate Tazemetostat and Pinometostat in Multiple Cancer Indications
Foundation Medicine Will Identify Individuals with Non-Hodgkin Lymphoma whose Tumors Possess EZH2 Mutations for Potential Enrollment into Epizyme's Phase 2 Clinical Trial
Investors in Epizyme Inc. saw new options become available this week, for the May 2017 expiration.
Third Epizyme-discovered product candidate advances into clinical development
Study Expands Tazemetostat Clinical Program into Patients with Relapsed or Refractory Mesothelioma Characterized by BAP1 Loss-of-Function
Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.
Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today it has entered into a collaboration agreement with Genentech, a member of...
Investors in Epizyme Inc. saw new options begin trading this week, for the February 2017 expiration.
Trade-Ideas LLC identified Epizyme (EPZM) as a weak on high relative volume candidate
Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today reported preliminary data from its ongoing, global Phase 2 clinical trial of orally administered...